Blood brain barrier permeability and therapeutic time window of Ginkgolide B in ischemia-reperfusion injury.

Weirong Fang,Yan Deng,Yunman Li,Erxin Shang,Fang Fang,Peng Lv,Li Bai,Yan Qi,Fang Yan,Lishun Mao
DOI: https://doi.org/10.1016/j.ejps.2009.10.002
IF: 5.112
2010-01-01
European Journal of Pharmaceutical Sciences
Abstract:The goal of this study was to estimate the blood brain barrier (BBB) permeability of Ginkgolide B in normal condition and models of ischemia both in vivo and in vitro. A sensitive LC-MS/MS analytical method was developed to determinate accurately the concentration of Ginkgolide B in cell, plasma and brain tissue. The injured rat brain microvessel endothelial cells (RBMECs) induced by Na2S2O4 served as a hypoxia/reoxygenation model in vitro. Intracellular concentration of Ginkgolide B increased in injured cells in a concentration-dependent manner. As a model of in vivo—ischemia/reperfusion, we performed middle cerebral artery occlusion (MCAO) in rats. Concentration of Ginkgolide B in the brain tissues showed higher in cerebral ischemia-reperfused animals than that in normal rats. To evaluate potential clinical effect of Ginkgolide B, we determined therapeutic time window in MCAO rats. Up to i.v. administration at 2h after reperfusion of rats, Ginkgolide B could decrease infarction volume and brain edema, exerting significant protective effect in cerebral ischemia injury. In conclusion, Ginkgolide B could pass through BBB, especially after ischemia–reperfusion injury of brain, and might be therapeutically effective for ischemia/reperfusion injury of human brain.
What problem does this paper attempt to address?